Mesenchymal stem cells: Immunobiology and therapeutic potential in kidney disease

被引:60
作者
McTaggart, Steven J.
Atkinson, Kerry
机构
[1] Queensland Child & Adolescent Renal Serv, Brisbane, Qld, Australia
[2] Mater Hosp, Brisbane, Qld, Australia
[3] Mater Med Res Inst, Brisbane, Qld, Australia
[4] Univ Queensland, Brisbane, Qld, Australia
关键词
acute renal failure; immunosuppression; mesenchymal stem cell; renal transplantation;
D O I
10.1111/j.1440-1797.2006.00753.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
aMesenchymal stem cells (MSC) are non-haematopoietic cells that are prevalent in the adult bone marrow but can also be isolated from a variety of other postnatal tissues. MSC are non-immunogenic and are immunosuppressive, with the ability to inhibit maturation of dendritic cells and suppress the function of naive and memory T cells, B cells and NK cells. In addition to their immunomodulatory properties, MSC are capable of differentiating into various tissues of mesenchymal and non-mesenchymal origin and migrating to sites of tissue injury and inflammation to participate in tissue repair. A number of studies in animal models of cardiac injury, stroke and ischaemic renal injury have demonstrated the clinical potential of MSC in tissue regeneration and repair. MSC are currently being evaluated in various preclinical and clinical studies in humans and offer significant potential as a novel cellular therapy for tissue regeneration and immunological conditions. The present review focuses on the unique immunomodulatory and regenerative properties of MSC and their potential role in the treatment of kidney disease.
引用
收藏
页码:44 / 52
页数:9
相关论文
共 67 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]  
Angoulvant D, 2004, BIORHEOLOGY, V41, P469
[3]   In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions [J].
Anjos-Afonso, F ;
Siapati, EK ;
Bonnet, D .
JOURNAL OF CELL SCIENCE, 2004, 117 (23) :5655-5664
[4]   Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells [J].
Arikawa, T ;
Omura, K ;
Morita, I .
JOURNAL OF CELLULAR PHYSIOLOGY, 2004, 200 (03) :400-406
[5]   Interleukin 10 is a growth factor for a population of regulatory T cells [J].
Asseman, C ;
Powrie, F .
GUT, 1998, 42 (02) :157-158
[6]   Immunogenicity of adult mesenchymal stem cells: Lessons from the fetal allograft [J].
Barry, FP ;
Murphy, JM ;
English, K ;
Mahon, BP .
STEM CELLS AND DEVELOPMENT, 2005, 14 (03) :252-265
[7]   Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo [J].
Bartholomew, A ;
Patil, S ;
Mackay, A ;
Nelson, M ;
Buyaner, D ;
Hardy, W ;
Mosca, J ;
Sturgeon, C ;
Siatskas, M ;
Mahmud, N ;
Ferrer, K ;
Deans, R ;
Moseley, A ;
Hoffman, R ;
Devine, SM .
HUMAN GENE THERAPY, 2001, 12 (12) :1527-1541
[8]   Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48
[9]   Studying the immunosuppressive role of indoleamine 2,3-dioxygenase:: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo [J].
Bauer, TM ;
Jiga, LP ;
Chuang, JJ ;
Randazzo, M ;
Opelz, G ;
Terness, P .
TRANSPLANT INTERNATIONAL, 2005, 18 (01) :95-100
[10]  
Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249